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Abstract
The extensive diversity of Plasmodium falciparum antigens is a major obstacle to a broadly effective malaria vaccine but
population genetics has rarely been used to guide vaccine design. We have completed a meta-population genetic analysis
of the genes encoding ten leading P. falciparum vaccine antigens, including the pre-erythrocytic antigens csp, trap, lsa1 and
glurp; the merozoite antigens eba175, ama1, msp’s 1, 3 and 4, and the gametocyte antigen pfs48/45. A total of 4553 antigen
sequences were assembled from published data and we estimated the range and distribution of diversity worldwide using
traditional population genetics, Bayesian clustering and network analysis. Although a large number of distinct haplotypes
were identified for each antigen, they were organized into a limited number of discrete subgroups. While the non-
merozoite antigens showed geographically variable levels of diversity and geographic restriction of specific subgroups, the
merozoite antigens had high levels of diversity globally, and a worldwide distribution of each subgroup. This shows that the
diversity of the non-merozoite antigens is organized by physical or other location-specific barriers to gene flow and that of
merozoite antigens by features intrinsic to all populations, one important possibility being the immune response of the
human host. We also show that current malaria vaccine formulations are based upon low prevalence haplotypes from a
single subgroup and thus may represent only a small proportion of the global parasite population. This study demonstrates
significant contrasts in the population structure of P. falciparum vaccine candidates that are consistent with the merozoite
antigens being under stronger balancing selection than non-merozoite antigens and suggesting that unique approaches to
vaccine design will be required. The results of this study also provide a realistic framework for the diversity of these antigens
to be incorporated into the design of next-generation malaria vaccines.
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Introduction
Infection with the protozoan parasite Plasmodium falciparum
causes more than 500 million episodes of clinical malaria and two
million deaths each year [1]. A broadly effective malaria vaccine
would have a significant global health impact on this enormous
public health burden. Over the past 40 years, an intensive
international effort has led to the development of several antigens
from P. falciparum as malaria vaccine candidates. They include
surface exposed proteins from morphologically distinct develop-
mental stages of the parasite lifecycle within the human host
namely the Circumsporozoite Surface Antigen (CSP), Thrombos-
pondin Related Adhesion Protein (TRAP), Liver Stage Antigen 1
(LSA1), Apical Membrane Antigen 1 (AMA1), Erythrocyte
Binding Antigen 175 (EBA175), Merozoite Surface Proteins
(MSPs 1–5), Glutamate Rich Protein (GLURP) and Pfs48/45
([2]; Table 1). Many of these antigens have undergone rigorous
developmental and preclinical testing as subunit vaccines [2] but
only a few have reached advanced clinical trials (e.g. Phase 2b:
CSP (RTS,S); AMA1 (FMP2.1, C1); MSP142 (FMP1); MSP3
(LSP)) [3]. The variable success of candidate malaria vaccines may
be due to the high degree of diversity of P. falciparum antigens [4]
and a variant-specific immune response [5,6], particularly as most
vaccines are formulated with a single polymorphic variant. There
is now increasing recognition that a malaria vaccine may need to
contain multiple variants of the target antigen to be effective
against an entire parasite population [7].
The extent and distribution of genetic diversity of P. falciparum is
for the most part associated with transmission intensity and
geographic origin [8,9], but unique patterns of diversity have been
observed for P. falciparum antigens. Because many antigens are
under immune selection, they are several times more diverse than
the neutral loci used in genome wide analyses. This is the case
even in low transmission regions [10,11,12], suggesting that
vaccines will need to represent a large number of variants
regardless of the region of deployment. The strong geographic
differentiation observed in genome-wide markers [8,9] is also
detectable in genes encoding the sporozoite antigen, csp [13,14,15]
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8497and to a greater extent, the gametocyte antigen, pfs48/45 [16],
raising the possibility that malaria vaccines may need to be tailored
for specific regions. However, a lack of geographic differentiation
has been observed for blood stage antigens such as ama1
[17,18,19], msp3 [20], msp4,5 [21] and S-antigen [22]. Ama1
variants have recently been shown to cluster into six genetically
distinct subgroups on the basis of antibody cross-reactivity, with all
subgroups being found worldwide. This study illustrated that
immune selection may play a role in structuring the diversity of
this highly polymorphic antigen. Consequently, a small number of
variants from distinct subgroups may give the sought after broad
vaccine coverage [18]. To inform the design of next generation
malaria vaccines, population genetic studies for each candidate
antigen in the spectrum of endemic regions will be essential. Such
analyses will help to prioritize candidates, advance our under-
standing of the geographic distribution of genetic diversity and
provide a framework for testing the immunological significance of
antigen diversity.
An enormous amount of research has highlighted the extensive
diversity of P. falciparum antigens [23], however the majority of
studies have focused on just one or two countries per antigen and
comparisonsamong studies haverarelytakenplace.Tofacilitatethe
design of broad-spectrum malaria vaccines, we have summarized
the known global range and distribution of genetic diversity of ten
leading malaria vaccine antigens for which population-level
sequence data was available. We collected sequences from natural
populations and laboratory-isolates and completed a population
genetic analysis using a variety of traditional and more recently
developed clustering tools. By comparative analyses we show
evidence that the diversity of non-merozoite antigens is largely
structured on the basis of geographic origin while for merozoite
antigens, the dominant targets of natural host immunity [24] a
relative lack of geographic structure was observed with the majority
of diversity being contained within each location. This meta-
population genetic analysis of ten leading malaria vaccine
candidates provides a framework by which to consider parasite
diversity in the design of the next generation of malaria vaccines.
Results
Data summary
More than 4500 sequences with an average length of 0.8 kb
were compiled from GenBank and the published literature for the
genes encoding twelve antigens that matched the inclusion criteria
(Tables 1, S1 and S2). Although msp2 and msp5 matched the
criteria we did not complete the population genetic analyses. For
msp2, this was due to the majority of sequences being comprised of
highly polymorphic repeats (with many gaps) flanked by only short
regions of unique sequence. Haplotypes could therefore only be
defined on the basis of differing numbers of repeats, resulting in an
overestimation of biologically significant diversity. For msp5, there
were only five haplotypes and preliminary analyses showed that
they were not structured within nor among populations (data not
shown), so diversity in this antigen was also unlikely to have major
biological significance. Among the remaining ten antigens, the
number of nonsynonymous polymorphisms (dN) was several-fold
greater than the number of synonymous polymorphisms (dS;
Table 1), which is an indication of immune selection in the P.
falciparum genome [4]. The population dataset included sequences
from the natural parasite populations of between 2 and 13
countries and a minimum of 2 geographical regions (namely
Americas (Central and South), Asia Pacific or Africa, Table S1).
The median sample size was 31 sequences (range=8–1368) per
country, and each country contained a median number of 8
distinct haplotypes (range=1–68) (Table 2). Only small sample
sizes were available for glurp and pfs48/45 so we caution that the
results for these antigens may be biased and thus should be
interpreted with care. To focus the analysis on the putative
antigenic diversity (i.e. polymorphisms that change protein
structure) the nonsynonymous single nucleotide polymorphism
(nsSNP) haplotypes were derived for all antigen sequences, except
for msp1, for which the majority of the data comprised only a 5
amino acid haplotype (corresponding to polymorphisms found
only in the MSP119 domain), so the remaining msp1 DNA
sequences were converted to the corresponding amino acid
Table 1. Summary of population genetic data collected for the genes encoding twelve P. falciparum vaccine antigens.
GENE EXPRESSION* LOCUS* DOMAIN NUCLEOTIDES nd N d S
csp Sporozoite PFC0210c C-terminal 909–1140 604 20 3
trap Sporozoite PF13_0201 N-terminal 1–993 100 70 4
lsa1 Liver stages PF10_0356 N-terminal 1–397 74 12 2
ama1 Merozoite PF11_0344 Region I 448–903 572 46 11
eba175 Sporozoite, Merozoite MAL7P1.176 Region II 433–2169 135 23 2
msp1 Merozoite PFI475w MSP119 4813–5863 2237 5
{ n.d.
msp2 Merozoite PFB0300c Blocks 2 & 3 1–816 392 n.d. n.d.
msp3 Merozoite PF10_0345 Dimorphic repeat
{ 106–523 124 75 18
msp4 Sporozoite, Merozoite PFB0310c All 1–816 142 16 3
msp5 Merozoite PFB0305c All 1–819 70 4 3
glurp Sporozoite, Liver, Blood, Gametocyte PF10_0344 Region 0 106–1353 48 22 7
pfs48/45 Gametocyte PF13_0247 All 1–1326 55 25 15
MEDIAN 817.5 129.5 22.5 3.5
TOTAL 10419 4553 313 68
*Source: PlasmoDB, www.plasmodb.org.
{gaps were deleted.
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combinations of nucleotides or amino acids with no particular
weight placed upon any position or change, rather all of the
following analyses were based on whether each polymorphic site
was the same or different.
Polymorphism and haplotype diversity
Comparing among countries for each antigen, the genes
encoding the non-merozoite antigens (csp, trap, lsa1, glurp and
pfs48/45; Table 1) showed variation in diversity as measured by
the polymorphism (k and P) and haplotype diversity (Hd)
statistics. Whereas, the genes encoding each of the merozoite
antigens (ama1, eba175 and msp1, msp3 and msp4;T a b l e1 )e a c h
showed similar levels of diversity among countries and regions
(Table 2). For example, csp was significantly more diverse in
African compared to Asia-Pacific countries (P,0.01) while for
ama1 there were no significant differences between African and
Asia-Pacific countries (P.0.05). Furthermore, for non-merozoite
antigens the degree of haplotype diversity was strongly correlated
with the amount of polymorphism (r=0.63, P,0.01), whereas
for the merozoite antigens, the amount of polymorphism (k and
P) varied widely among antigens but Hd was almost always high
(Figure 1; Table 2; r=0.13; P.0.05). Therefore, haplotype
diversity varied widely among countries and regions for non-
merozoite antigens in association with transmission intensity and
polymorphism, but was consistently high for the merozoite
antigens irrespective of transmission intensity and levels of
polymorphism suggesting that the latter are under stronger
balancing selection.
Genetic differentiation and gene flow
To determine how the observed diversity was distributed among
countries, population structure was first inferred by measuring
genetic differentiation among countries both within and among
regions. To do this we calculated FST from haplotype-frequencies
and pairwise DNA sequence diversity, although only the former
was calculated for MSP1 (see Materials and Methods). The
haplotype frequency-based statistics are more sensitive for small
sample sizes, while the sequence based statistic is a more sensitive
method for detecting population structure in highly polymorphic
loci [25], (see Text S1 for specific examples). Significant
differentiation was identified among regions for all P. falciparum
vaccine antigens, albeit to a lesser degree for lsa1, ama1, eba175 and
Table 2. Estimates of diversity for the genes encoding ten P.
falciparum vaccine antigens.




csp Americas Brazil 31 5 1.35 5.85 3 0.28
Venezuela 10 13 6.24 27.9 6 0.89
Asia Pacific Vanuatu 136 2 0.62 2.7 2 0.31
Indonesia 36 8 0.65 2.83 5 0.26
Vietnam 143 14 2.06 8.9 20 0.7
Thailand 26 13 2.95 12.76 8 0.76
Myanmar 25 6 1.08 4.68 4 0.41
India 11 2 0.8 4.25 3 0.47
Iran 91 3 1.08 4.68 5 0.6
Africa Kenya 18 17 5.73 25.29 13 0.93
Cameroon 9 12 4.56 19.72 7 0.94
The Gambia 44 18 5.97 25.83 21 0.95
Senegal 10 10 4.73 20.49 8 0.96
trap Asia Pacific Thailand 29 22 5.6 6.12 25 0.99
India 8 30 9.89 10.86 8 1
Africa The Gambia 48 46 11.58 12.13 37 0.98
lsa1 Americas Brazil 19 8 1.81 4.83 6 0.7
Asia Pacific Papua New
Guinea
20 7 2.31 6.07 7 0.88
Malaysia 10 3 1.02 3.97 3 0.51
Africa Kenya 22 8 2.18 6.12 7 0.83
ama1 Americas Venezuela 10 19 7.27 18.71 6 0.78
Asia Pacific Papua New
Guinea
162 34 11.11 26.3 27 0.94
Thailand 55 30 10.75 25.5 19 0.94
India 101 44 9.72 24.31 68 0.99
Africa Kenya 8 24 9.54 24.2 8 1
Nigeria 51 34 11.39 27.14 35 0.98
Mali 61 37 11.1 26.97 40 0.98
Benin 22 30 9.99 25.08 20 0.99
eba175 Asia Pacific Thailand 48 18 6.23 3.81 17 0.9
Africa Kenya 39 18 6.01 3.47 23 0.9
Nigeria 30 16 5.53 3.19 15 0.81
msp1 Americas Brazil 138 n.a. n.a. n.a. 7 0.71
Peru 135 n.a. n.a. n.a. 1 0
Asia Pacific Solomon Is. 77 n.a. n.a. n.a. 4 0.61
Vanuatu 140 n.a. n.a. n.a. 3 0.61
Phillippines 57 n.a. n.a. n.a. 5 0.74
Vietnam 77 n.a. n.a. n.a. 5 0.56
Thailand 72 n.a. n.a. n.a. 5 0.64
India 51 n.a. n.a. n.a. 10 0.83
Iran 92 n.a. n.a. n.a. 5 0.8
Africa Kenya 18 n.a. n.a. n.a. 6 0.77
Mali 1368 n.a. n.a. n.a. 15 0.76
msp3 Asia Pacific Thailand 50 75 27.94 96.62 9 0.71
Africa Nigeria 51 86 30.33 106.63 12 0.81
msp4 Asia Pacific Papua New
Guinea
42 9 2.42 3.1 14 0.92
Cambodia 12 9 2.74 3.36 9 0.94
Thailand 15 9 2.8 3.43 10 0.93




Africa Senegal 41 15 2.88 3.87 23 0.95
glurp Americas Brazil 9 9 4.78 3.85 5 0.72
Asia Pacific Myanmar 10 9 3.2 2.58 9 0.98
Africa Senegal 11 1 0.18 0.15 2 0.18
pfs48/45 Americas Venezuela 9 12 2.94 3.06 6 0.83
Asia Pacific Thailand 10 4 0.8 0.6 2 0.2
India 10 8 1.91 1.59 4 0.53
Africa Kenya 15 11 2.67 3.94 8 0.88
n=number of sequences, S=number of variant sites, h=number of haplotypes,
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differentiation was accompanied by limited gene flow (Nm) for all
antigens except for low-moderate levels for lsa1, ama1 and eba175
and very high for msp4 (Table 3C). Differentiation was also
detected within the Americas for csp and msp1 (the only antigens
for which we had multiple populations within this region), within
the Asia Pacific for csp, trap, ama1 and msp1, and significant but low
levels of differentiation within Africa for ama1 (Table 3). For
MSP1, the Asia-Pacific countries spanned a broad area.
Accordingly, pairwise comparisons identified differentiation be-
tween the Pacific and mainland Asian countries (FST=0.06–0.31;
P,0.01). Significant differentiation was also observed in pairwise
comparisons of countries from East (Vietnam, Thailand) and West
(India, Iran) mainland Asia (FST=0.09–0.27; P,0.001) with no
structure among countries within these subregions (FST=0,
P.0.05; 0.03, P,0.05 respectively). Additional structure was
detected among the Pacific island nations (FST=0.07–0.21;
P,0.01). We also observed significant differentiation between
local populations such as Vanuatu’s islands for csp (Pentecost
compared to Gaua: FST=0.14; P=0.02; and Malakula:
FST=0.19; P,0.01) and MSP1 (all comparisons, FST=0.17–
0.54; P,0.01) and distant locations of India for MSP1 (FST=0.32;
P,0.001). No such structuring was observed for csp within Brazil
or Myanmar, ama1 in PNG or Thailand, msp1 in Vietnam, nor
msp4 in Senegal (Table S1).
Clustering and networks
In the analysis so far, individuals were grouped by geographic
location, assuming that geography (or other associated variables
e.g. host genetics, vector species) will be the dominant barrier to
gene flow. It is possible that these somewhat arbitrary groupings
might incorrectly estimate population structure, or fail to identify
within population subdivision, although where possible, we
measured genetic differentiation within a country as described
above (Table S1). To address this, and to identify subgroups of
related nsSNP (or for MSP1, amino acid) haplotypes that are
genetically and thus potentially antigenically distinct, we also used
a Bayesian clustering algorithm [26,27] and confirmed the results
using network analysis (see Materials and Methods). The Bayesian
algorithm groups related haplotypes into a predefined number of
clusters (K) on the basis of shared allele frequencies. Each
haplotype is then assigned a membership coefficient (Q) to each
of the clusters with the majority of the haplotypes being assigned to
only one cluster at ‘‘true’’ K (Figure 2 A–J) and variability in the
data increasing thereafter (Figure S1; [26,27]). Using this
approach we found a small number of distinct clusters for all
antigens (Kmean=4.5, Krange=3–6). Although admixed haplotypes
(,75% membership to any one cluster) were prevalent for trap,
ama1, eba175 and msp4 (Figure 2 B, D, E and H), increased
estimates of K resulted in even higher proportions of admixed
haplotypes (Figure S2) thus confirming that the distribution of the
Figure 1. The relationship between polymorphism and haplo-
type diversity of the genes encoding ten P. falciparum vaccine
antigens. Non-merozoite antigens are represented by a solid symbol
and merozoite antigens by an open symbol.
doi:10.1371/journal.pone.0008497.g001
Table 3. Estimates of genetic differentiation and gene flow
for the genes encoding ten P. falciparum vaccine antigens.
AMONG COUNTRIES AMONG REGIONS
AFRICA ASIA PACIFIC AMERICAS
A.
csp 0.02** 0.08*** 0.27*** 0.21***
trap n.a. 0.0021 n.a. 0.007**
lsa1 n.a. 0.05* n.a. 0.09***
ama1 ,0.01 0.02*** n.a. 0.03***
eba175 0.01 n.a. n.a. 0.05***
msp1 0.03 0.18*** 0.42*** 0.22***
msp3 n.a. n.a. n.a. 0.07***
msp4 n.a. 0.01 n.a. 0.02**
glurp n.a. n.a. n.a. 0.30***
pfs48/45 n.a. 0.03 n.a. 0.20***
B.
csp 0.02 0.08*** 0.29*** 0.25***
trap n.a. 0.12*** n.a. 0.12***
lsa1 n.a. 0.03ns n.a. 0.09**
ama1 0.01* 0.02*** n.a. 0.03***
eba175 ,0 n.a. n.a. 0.07***
msp1 n.a. n.a. n.a. n.a.
msp3 n.a. n.a. n.a. 0.11***
msp4 n.a. 0.01 n.a. 0.02*
glurp n.a. n.a. n.a. 0.40***
pfs48/45 n.a. ,0 n.a. 0.22***
C.
csp 10.56 2.24 0.37 0.70
trap n.a. 0.30 n.a. 0.40
lsa1 n.a. 3.37 n.a. 1.76
ama1 6.63 8.34 n.a. 3.36
eba175 239.11 n.a. n.a. 2.03
msp1 8.08 1.14 0.35 0.89
msp3 n.a. n.a. n.a. 0.85
msp4 n.a. 222.24 n.a. 38.48
glurp n.a. n.a. n.a. 0.18
pfs48/45 n.a. 24.82 n.a. 0.65
*0.01,P,0.05.
**0.001,P,0.01; P,0.001; n.a. not applicable.
For each antigen, FST statistics were calculated from both (A) haplotype
frequencies and (B) sequence diversity (except for MSP1 for which only
haplotype frequencies were used) and (C) gene flow (Nm). Nm.1 is considered
a high level of gene flow. The P-values shown in the key are for FST only and
were not available for Nm.
doi:10.1371/journal.pone.0008497.t003
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Network analysis differs in that it simply shows connectivity among
all haplotypes on the basis of shared SNPs and allows for the
visualization of recombinant haplotypes that bridge the major
subgroups. If haplotypes differed by fewer nsSNPs than the
predefined threshold (t), they were connected, and if greater than t
they were not. We used a t-value that connected the majority of
haplotypes so all relationships could be examined in one network,
and for clarity. The results supported the cluster analysis with
haplotypes grouping into a small number of tightly connected
lobes that corresponded to each of the structure defined subgroups
(Figure S3). Bridging connections were predominantly character-
ized by admixed haplotypes or entire subgroups (e.g. ama1, msp4)
as defined by the cluster analysis and suggest that these comprise
recombinant haplotypes (Figure S3).
To determine whether the above-defined ‘‘subgroups’’ were
geographically restricted, for the Bayesian cluster data we plotted
the average Q for each country (Figure 2 K–T), and calculated the
average frequency of haplotypes with membership to the
predominant subgroup (fm) and the population diversity (Pd)a
simple measure of the distribution of clusters that is analogous to
the Hd (see above and Materials and Methods). Globally (i.e.
comparisons among all countries), the cluster analysis supported
the high levels of differentiation among regions for the non-
merozoite antigens with a high frequency of haplotypes belonging
to one subgroup (fm=69.568%) and low population diversity
(Pd=0.4060.07), albeit lsa1 showed low to medium frequencies of
all clusters in PNG (Pd=0.80) and Kenya (Pd=0.74; Figure 2 M;
Table S3). In contrast, all of the merozoite antigens showed low to
medium frequencies of all clusters in all countries (fm=45.867%)
and high population diversity (Pd=0.6460.07), although the
frequency of each cluster was variable among countries (Figure 2
N–R; Table S3). These variations in frequency were consistent
with the moderate geographic differentiation described above.
The network analysis further supported these results with the non-
merozoite antigen haplotypes being most strongly connected with
others originating from the same geographic region (Figure 3 A–C,
I, J), whereas for the merozoite antigens, haplotypes from different
regions often connected within the same lobes of the network
(Figure 3 D–H). These analyses also supported the diversity
analyses with (for example) the highly diverse African csp and trap
haplotypes being loosely or disconnected from the main network
(Figure 3 A, B), whereas geographic origin did not correlate with
the connectivity of the ubiquitously diverse merozoite antigen
haplotypes to the network (Figure 3 D–H).
Within regions, the significant differentiation detected in the
Americas for both csp and MSP1 (Table 3), was supported by the
cluster analysis (note that network analysis is not presented at this
or any finer resolution). For csp the majority of haplotypes showed
membership to one cluster, albeit different clusters for each
country (Figure 2K; Table S3). For MSP1, a single cluster was
found in Peru (1 haplotype, Table 2) and 4 clusters (7 haplotypes;
including that found in Peru) were found in Brazil (Figure 2P;
Table S3). In the Asia-Pacific region, for trap the differentiation
between Thailand and India was supported by the cluster analysis
(Figure 2L; Table S3). Whereas, for csp, lsa1, ama1 and MSP1
varying degrees of support were given to the differentiation
Figure 2. Global population structure of the genes encoding
ten P. falciparum vaccine antigens based on Bayesian cluster
analysis. Membership coefficients for A–J) individual nsSNP haplo-
types and K–T) the population average for the estimated number of
clusters (K, shown on the left of the two histograms). In the latter,
countries from different continents are separated by a blank space and
organised from east on the left, to west on the right with vaccine
haplotypes on the far right hand side. An asterisk denotes countries for
which fewer than 8 haplotypes were available that were taken from
dataset 2 (Table S2). Dark blue=cluster 1; Red=cluster 2; Green=
cluster 3; Purple=cluster 4; Light blue=cluster 5; Orange=cluster 6.
doi:10.1371/journal.pone.0008497.g002
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countries albeit at variable frequencies (Figure 2 K, M, N and P).
For csp, a single cluster was predominant among all Asia-Pacific
countries, with low frequencies of haplotypes belonging to a
second cluster. The majority of Iranian haplotypes clustered with
the Asia-Pacific cluster and a minor proportion with the African
cluster, a structure that is consistent with Iran’s central location
between these two regions. For lsa1, all clusters were found in
PNG, but only 2 in Malaysia. A limited degree of differentiation
between the two countries (Table 3), and lower diversity in
Malaysia (Table 2) suggests that it shares haplotypes with PNG.
For ama1, all clusters were present in each country at variable
frequencies and high population diversity (Figure 2N, Table S3).
This is consistent with a previous report [18], albeit our dataset
contained 3.6 times the number of haplotypes (Table 1). For
MSP1, the differentiation seen among Asia-Pacific subregions was
supported by variable frequencies of the four clusters (Figure 2 P;
Table S3). The remaining two antigens studied in the Asia Pacific,
msp4 and pfs48/45, showed strong similarities in the cluster
analysis (Figure 2 R, T) demonstrating a lack of population
structure for these antigens in this region. Among African
countries, the cluster analysis confirmed a lack of population
structure with strong similarities among countries for the four
antigens for which multiple African sites were sampled (Figure 2
K, N–P). To identify local population structure, we investigated
differences among locations within the same country. The results
show that only MSP1 and pfs48/45 were structured among locales
within a country (Figure S4).
Prevalence of vaccine haplotypes
The majority of haplotypes upon which current vaccines are
based were found to be present, but at extremely low frequencies
in the global parasite population, with higher frequencies observed
only for lsa1 and MSP1 vaccine haplotypes (Table 4). Because
distinct haplotypes may be different by as few as one nsSNP, which
is less likely to encode antigenic differences than multiple nsSNPs,
the breadth of biologically significant similarities may be
underestimated by this analysis. Therefore, we also included
vaccine haplotypes in the cluster (Figure 2 K–T) and network
analysis (Figure 3) to identify their associated subgroups. MSP1
vaccine haplotypes grouped with three distinct subgroups of the
four defined (Figure 2 P; Figure S3 F), each representing the most
common haplotypes. For the remaining antigens, the subgroups to
Figure 3. Global population structure of the genes encoding
ten P. falciparum vaccine antigens based on network analysis.
Networks of nsSNP haplotypes were drawn by first removing multiple
copies of each haplotype , leaving only one copy per country for the
analysis. Hence, identical haplotypes from different regions, but not
within regions were included. Each node (coloured circle) represents a
haplotype, shaded by region of origin: Red=Africa, Green=Asia,
Blue=Americas. Nodes are tied by edges (black lines) demonstrating
that they share a predefined threshold (t) of nsSNPs for csp=24;
trap=67; lsa1=8; ama1=48; eba175=18; msp1=5; msp3=63;
msp4=19; glurp=18; pfs48/45=23. Vaccine haplotypes are shaded in
yellow. Haplotypes originating from isolates with unknown origin are
shaded in white (unless they were vaccine haplotypes).
doi:10.1371/journal.pone.0008497.g003
Table 4. Worldwide prevalence of P. falciparum antigen
haplotypes that are components of malaria vaccines.
GENE VACCINE* HAPLOTYPE PREVALENCE
csp 3D7 1 0.01
trap T9/96 59 0.01
lsa1 3D7 1 0.23
ama1 3D7, FVO 2, 3 0.06, 0.06
eba175 FVO 2 0.13
msp1 3D7, FVO, FUP 1, 2, 3 0.16, 0.28, 0.26
msp3 FC27 6 0.10
msp4 3D7 1 0.13
glurp FVO 8 0.06
pfs48/45 NF54 11 0.09
*Names of laboratory isolates used for vaccine development.
doi:10.1371/journal.pone.0008497.t004
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in all populations (ama1, eba175, msp3, msp4, glurp, pfs48/45)
(Figure 2) or were geographically restricted (csp, trap, lsa1) (Figure 2,
3). All of the laboratory isolates (Table S2) were also included in
the cluster and network analysis. This allowed the assignment of
these isolates to haplotypes and structure defined clusters, thus
providing a framework for experiments to test the biological
significance of diversity and identifying the most distinct
haplotypes for diversity-covering vaccines (Table S4; [18]).
Discussion
To provide a rational framework for incorporating diversity into
the next generation of malaria vaccines, we have completed a
meta-population genetic analysis and thus summarised the known
global range and natural distribution of diversity for ten leading
malaria vaccine candidates. There are many natural population
datasets available from previous studies and there is a strong
precedent for comparing multiple datasets for such studies even
when only small numbers of samples are available (e.g. [17,28]).
Sample size was a limitation for the population genetic analysis of
some antigens and locations, however the majority of natural
populations (.70%) were represented by at least 20 sequences.
For populations with less than this number of sequences the results
should be interpreted with care. Despite these small sample sizes,
similar results to other countries from the same region were
observed. For example, Indian csp sequences (n=11) showed a
similar pattern of diversity to other Asian countries with larger
sample sizes (n=25–143), as did Thai and Indian pfs48/45
sequences (n=10 for both). We also used haplotype frequencies to
measure differentiation, which has been shown to be more reliable
than sequence diversity for smaller sample sizes [25] but results for
both statistics were similar for antigens with smaller sample sizes
(lsa1, glurp, pfs48/45). The patterns of diversity and geographic
population structure observed for these antigens warrant further
investigation by deep sampling in each geographic region. Another
potential source of bias is the combination of data from different
time points and from patients with different clinical status (Table
S1). Frequency dependant selection acts on antigens under strong
immune selection [29] resulting in changes in allele frequency over
time, and thus may exaggerate differentiation or alter cluster
frequencies seen among countries within the same region, such as
that observed for ama1 and MSP1 in the Asia-Pacific. Clinical
samples may also be biased toward particular antigen haplotypes
[30,31,32,33]. Nevertheless the differences among countries
(particularly evident in the large Asia-Pacific region) appeared to
increase with geographic distance, independently of both time and
clinical definition (Table S1), so these factors should not change
the overall conclusions of this study. A phenomenal amount of
additional sampling and sequencing, requiring a vastly inflated
budget and a major international consortium would be needed to
address these sampling issues. Our strategy, in using population
genetic data already generated and freely available has revealed
important insights into the overall organization of genetic diversity
of vaccine antigens and provides a framework for future studies to
improve malaria vaccine design.
By comparing the diversity found in different countries
worldwide we demonstrated that csp, and to a lesser extent trap
and lsa1 showed similar patterns to that of putatively neutrally
evolving microsatellite and SNP markers [8,34,35]. The highest
levels of diversity were found in Africa where transmission is
holoendemic (very high), the lowest in the Americas where it is
hypoendemic (low) and moderate levels in the Asia-Pacific where
transmission ranges from meso-hyperendemic (medium to high).
This suggests that transmission plays a predominant role in the
diversification of these non-merozoite antigens, and the similarities
to neutral markers suggest that these genes are not under strong
balancing selection. Glurp and pfs48/45 also showed similarly
variable diversity but there was no apparent trend for higher
diversity in Africa compared to other regions and as mentioned
above the small sample size for these antigens makes it difficult to
draw solid conclusions. For the merozoite antigens, the observa-
tion of high levels of haplotype diversity among countries at
different ends of transmission spectrum even for antigens with low
levels of polymorphism (e.g. eba175, msp4) suggests that recombi-
nation generates a number of different haplotypes even where
significant functional constraints exist. Together with immunolog-
ical evidence that blood stage antigens are major targets of natural
host immunity [24], this is a strong indication of balancing (e.g.
immune) selection. Immune selection favours a low-medium
frequency of distinct haplotypes and thus increased probability
of newly infecting parasites carrying antigenically distinct haplo-
types to those previously encountered by the host. Therefore, if
vaccine candidates are prioritized on the basis of low levels of
polymorphism, careful consideration must also be given to
distribution of haplotypes within natural populations.
A successful malaria vaccine will need to target a large
proportion of the parasite population, but it would not be feasible
to vaccinate individuals with the large numbers of haplotypes we
have described. A single haplotype will have some capacity to elicit
cross-reactive responses against those that are genetically similar but
the exact amount of polymorphism that defines antigenically
different haplotypes is not well understood. Recent work has
shown that ama1 haplotypes were organized into six strongly
differentiated subgroups by the Bayesian algorithm implemented
in the program structure [27,36]. In this study, evidence from
invasion inhibition assays suggested that haplotypes from the same
subgroup were antigenically similar and thus able to elicit cross-
reactive antibody responses, whilst those from different subgroups
were antigenically distinct [18]. Therefore, clustering tools may be
useful in defining biologically significant variation in P. falciparum
antigens. Our analysis used two different clustering tools to
subgroup the compiled haplotypes, namely the Bayesian clustering
and network analysis. Our dataset contained a much larger
number of ama1 sequences (n=572, compared to 158 in the
previous study [18]), with several additional natural populations,
yet did not identify any further subgroups. By completing these
analyses for all of the leading vaccine antigens in our study we
found as few as three, and no more than six subgroups for any
antigen in the worldwide parasite population. This suggests that
for all ten of the leading vaccine antigens, it may be feasible to
cover diversity by inclusion of a small number of carefully selected
haplotypes from each subgroup. However, a large number of
admixed haplotypes in the cluster analyses or bridging connections
among major lobes in the network analyses indicates recombina-
tion occurs among subgroups and that there is potential for the
evolution of further antigenically distinct haplotypes. Notably,
three of the four antigens for which these putative recombinants
were common were merozoite antigens (ama1, eba175 and msp4). A
series of experiments now needs to be done for each antigen to
verify the immunological relevance of the patterns observed, the
haplotypes from each subgroup that will elicit broadly protective
immune responses, and to quantify the contribution of each
polymorphism to antigenic diversity.
The geographic distribution of the defined diversity must also be
a consideration in the design of a broad-spectrum malaria vaccine
because significant variation among regions would suggest a need
for vaccines to be tailored accordingly. When we investigated the
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antigens we found stark contrasts among antigens from the
different developmental stages of the parasite lifecycle. Although
tests of genetic differentiation and gene flow among countries
suggested among-region structuring of diversity for all antigens,
stronger differentiation among countries and/or regions was found
for the non-merozoite antigens. The cluster and network analyses
supported strong among region structure (and lower within
location diversity) for csp, pfs48/45 and glurp and that within
regions for trap and lsa1, albeit much weaker geographic
structuring for the latter antigen. By contrast, the merozoite
antigens generally had lower levels of among and within region
differentiation and gene flow, and haplotypes formed subgroups
independent of geographic origin with uniformly high levels of
within population diversity. These comparative analyses confirm
that there are extreme differences in the population structure of
different types of antigens and thus may explain why paradoxical
estimates of the most recent common ancestor of P. falciparum have
been obtained in the past by evolutionary biologists using these
markers (reviewed in [37]). Interestingly, the cluster analyses also
showed differing frequencies of shared subgroups among coun-
tries, which were previously shown to vary over time for ama1 [18].
This may reflect both geographic isolation and natural fluctuations
over time as a result of frequency dependent selection or may
simply be the result of the variable sample collection mentioned
above. For MSP1, strong differentiation and a variable cluster
frequency among sub-regions and island nations of the Asia-
Pacific suggests that the biogeography of this region constitutes a
strong barrier to gene flow. If the subgrouping of haplotypes is
immunologically significant, current vaccine formulations may
only target parasites carrying haplotypes from the same subgroup,
giving those carrying haplotypes from distinct subgroups a
selective advantage. To give a greater probability of broad
efficacy, a population-specific vaccine strategy incorporating
haplotypes representative for the region may be effective for the
non-merozoite antigens while a diversity-covering approach may
be necessary for the merozoite antigens.
There are a number of possible explanations for the contrasting
population structures of P. falciparum antigens. The stronger
geographic population structure observed in the non-merozoite
compared to the merozoite antigens may at least in part driven by
the biology and kinetics of the lifecycle, with shorter, less frequent
exposures to human immunity. Therefore, a background of
geographic barriers or other location-specific environmental
factors will shift the distribution of diversity among populations.
This is a possibility for csp and trap which are expressed on the
surface of a small number of sporozoites (,20 parasites) that
rapidly migrate to the liver after inoculation into the human host
by the mosquito and pfs48/45 which is expressed only in the
mosquito stages [38,39,40,41,42]. Similarly, lsa1 is expressed by
liver schizonts but is a strong target of naturally acquired
immunity [39,43,44], in agreement with the weaker geographic
structuring of this antigen. Glurp is unusual because it is expressed
in a number of stages exposed to the human immune response
including on the sporozoite, liver schizont, merozoite and
gametocyte [38] and shows very strong geographic structuring,
however it is possible that the small sample size for each
population has overemphasised the diversity among locales. Other
region-specific factors that may decrease gene flow among P.
falciparum populations include human genetic polymorphisms that
confer resistance to malaria [45] and adaptation to different
anophelene species that transmit P. falciparum worldwide [46].
These ‘‘bottlenecks’’ may lead to population structure in genes
expressed during the human or mosquito stages respectively, and
in neutral loci as markers of the underlying population biology
[8,35]. For the merozoite antigens the diversity within populations
may be high as a result of exposure to the host immune response.
These antigens are all exclusively expressed during the merozoite
stage except for eba175 and msp4, which are also expressed in the
sporozoite [47,48,49]. Merozoite exposure is brief (,2 mins), but
it occurs repeatedly at a high parasitemia (.10,000 parasites in the
first cycle, thereafter increasing exponentially) so there are many
opportunities for immune selection. Some diversification of
merozoite antigens may be adaptations to polymorphisms in
erythrocyte receptors essential for parasite invasion [50]. Finally,
antigens from both groups that are expressed in the mosquito
stages (i.e. csp, trap, eba175, msp4, glurp and pfs48/45) may be
exposed to immune selection by the anophelene vector (e.g. csp
[14]). In support of the biological significance of the contrasting
population structures observed, balancing selection has been
detected in all of the merozoite antigens [51,52,53,54,55] whereas
for the non-merozoite antigens, balancing selection was detected
in trap and pfs48/45 [56,57] but not in csp [57] and lsa1 [58] (glurp
has not been investigated). Furthermore, a vaccine-mediated
haplotype-specific immune response was detected for recombinant
vaccines based upon msp1 [59] and msp2 [6] but not for csp [60,61]
suggesting that different haplotypes are antigenically distinct for
the former two antigens. The results of our study are consistent
with the structuring of diversity by balancing selection for the
merozoite but not for the non-merozoite antigens.
This investigation has revealed a possible framework by which
to formulate malaria vaccines with a greater potential for broad
protection against the enormous diversity of parasite antigens. It
may be possible to tackle the neglected problem of antigen
diversity in malaria vaccine design by inclusion of the most
prevalent haplotype(s), or a diversity-covering vaccine with
inclusion of at least one representative haplotype from each of
the defined subgroups of haplotypes. Because they show different
population structures, the former approach may be more
appropriate for the non-merozoite antigens, and the latter for
the merozoite antigens. The haplotype and subgroup classification
for a number of laboratory isolates are available in the supporting
online material (Table S4) as a first step to guide the selection of
such haplotypes, and to help define immunological correlates of
protection which are now urgently needed to support these
important findings. Nevertheless, if these contrasting population
genetic structures of the genes encoding P. falciparum antigens are
considered in the design of next generation vaccines, perhaps the




The P. falciparum antigens selected for the study were key
components of malaria vaccines in the late stages of development
or in recent trials [2,3]. To be included in the study, we searched
for population data - which we defined as 8 or more sequences
from a defined location (e.g. a village or town) - for a minimum of
two countries for each antigen. DNA sequences (and amino acid
polymorphisms for MSP1) were then obtained for the twelve
antigens meeting these criteria, including surface proteins
expressed during several different lifecycle stages (Table 1).
Sequences were collected from GenBank and further sequences
or haplotypes were reconstructed from published data. If only the
haplotypes and frequencies were available the appropriate number
of copies for each allele was added to the dataset to ensure natural
population frequencies (Table S1). Additional sequence data from
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collected, including those upon which vaccines have been based
(Table S2). These sequences were included in the calculation of
the (known) extent of diversity worldwide (Table 1) and in the
cluster analyses to maximize the sample number and provide a
reference for vaccine development. Tables S1 and S2 contain
summary information (e.g. GenBank accession numbers, refer-
ence) for each of these dataset. The sequences and haplotypes are
available from the authors upon request. For msp1 and msp2 all
DNA sequences were translated using TranSeq (http://www.ebi.
ac.uk/Tools/emboss/transeq/). For simple multiple alignments
with few gaps, DNA sequences were aligned using Sequencher 4.8
(Gene Codes, Ann Arbor, MI). Amino acid alignments (MSP1 and
MSP2) were done using Clustal W [62]. Gaps were removed from
all alignments because indels and repeats evolve by different
mechanisms to SNPs and may result in false estimates of
biologically significant diversity. We also removed invariant sites
and synonymous SNPs to simplify the haplotype and focus the
analysis only on the putative antigenic diversity. The resultant
nonsynonymous SNP (nsSNP) haplotypes or polymorphic amino
acid haplotypes (for MSP1 and MSP2) were then used for
population genetic analysis.
Population Genetics
Population genetic analyses were first done with the complete
dataset (Tables S1 and S2) to investigate the global range of
diversity as well as the frequency of haplotypes being used in
vaccine development, while the population dataset (Table S1) was
used to investigate the range and distribution of diversity within
and among the natural P. falciparum populations of individual
countries. Population genetic parameters were determined using
DnaSP v. 4.20.2 [63]. However, for MSP1 and MSP2 amino acid
sequences we used Arlequin v. 3.1.1 [64] because DnaSP only
handles DNA sequences. As measures of diversity we defined the
polymorphism by counting the total number of synonymous (dS) and
number of nonsynonymous (dN) SNPs; and by calculating from
nsSNP haplotypes, the number of polymorphic sites (S), the
average pairwise number of polymorphisms (k) and from complete
DNA sequences (minus any gaps) the nucleotide diversity (P), the
latter being a proportional measure of polymorphism that can be
compared among antigens. Additional measures of diversity
calculated included the number of distinct haplotypes (h) (although
this is heavily biased by sample size) and the haplotype diversity which
is analogous to the heterozygosity (Hd=[n/(n21)][(12S(fi)
2)]
where n is the sample size and f is the frequency of the i
th allele)
and can also be compared among antigens. The Mann-Whitney
test was used to compare polymorphism or diversity among
regions where at least 3 countries were included per region (or
subregion). Spearman’s rank correlation coefficient (r) was used to
measure associations between polymorphism (P) and diversity
(Hd). Statistical analysis was done using SPSS v. 17.
To assess population structure we first estimated the genetic
differentiation (i.e. the difference in the average diversity within
compared to that among populations) for each antigen by
calculating FST from both haplotype frequencies and pairwise
sequence diversity. For comparisons among countries or regions
for all antigens except MSP1, two transformed FST statistics
available in DnaSP, were calculated namely HST which is loosely
based on Hd, and KST* based on k. Importantly, both HST and
KST* are weighted for variable population size [25]. Significance
was tested by comparison with 95% confidence intervals from
1000 permutations [25]. For comparisons among defined natural
populations within a country (i.e. .8 sequences in each) we
calculated Weir and Cockerhams h [64] from the pairwise
sequence diversity (i.e. analogous to KST*) in Arlequin. For
MSP1 we measured the equivalent to HST available in Arlequin
software, namely Weir and Cockerhams h [64] calculated from
haplotype frequencies. Significance was tested by the permutation
test. Gene flow (Nm) was calculated using the method of Hudson et
al. [65]. Population structure was also assessed using the Bayesian
clustering algorithm implemented in structure v. 2.2 [27,36], which
assigns individual multi-locus genotypes probabilistically to a user-
defined number of clusters (K) [27]. For each set of antigen
haplotypes, structure was run 20 times for K=1–10 for 10,000
Monte Carlo Markov Chain (MCMC) iterations after a burn-in
period of 10,000 [66] using the admixture model and correlated
allele frequencies. The mean log probability of the data (LnP[D])
and its standard deviation was plotted to predict the optimal value
for K. Membership coefficients (Q) were then averaged across
individuals within countries and/or regions to reveal any
geographic association of the resultant clusters. To quantify the
distribution of clusters within a geographically defined region we
developed a population diversity statistic, Pd, where Pd=12g( fi )
2,
where fi is the frequency of the i
th cluster (analogous to Hd). A low
Pd (,0.5) indicated that the geographically defined population
(e.g.. country, village) has parasites with predominant membership
to one cluster, and high Pd (.0.5) indicated membership to
multiple clusters with low-medium frequencies. We confirmed the
cluster analysis by visualizing the relationships between isolates
using a transparent network analysis technique which simply
connects isolates, represented as nodes within a network, based
on shared SNPs. Unlike phylogenetic methods there is no
evolutionary model behind network construction, but a simple
threshold was used to define where an edge was drawn. For each
antigen, this threshold was defined so as best to visualize the
relationships between isolates, and in particular the recombinant
isolates. The software program R and the ‘network’ package was
used to construct and visualize the antigen networks [67,68].
Supporting Information
Text S1 Haplotype-frequency vs. sequence based F-statistics and
supporting references
Found at: doi:10.1371/journal.pone.0008497.s001 (0.13 MB
DOC)
Figure S1 Log probability of the data plots for Bayesian cluster
analysis. LnP(D) is shown for nsSNP haplotypes of (A) csp, (B) trap,
(C) lsa1, (D) ama1, (E) eba175, (F) msp1, (G) msp3, (H) msp4, (I) glurp
and (J) pfs48/45. A plot of the log probability of the data, LnP(D)
against all estimates of the number of clusters, K, was used to
estimate the true value of K. LnP(D) typically plateaus or continues
to increase slightly when true K has been reached (68). The error
bars represent the mean value of 20 replicate runs at each K value.
For some antigens, LnP(D) did not plateau with increasing K,i n
which case the lowest value that captured the major structure in
the data was chosen (69).
Found at: doi:10.1371/journal.pone.0008497.s002 (0.36 MB TIF)
Figure S2 Bayesian cluster analysis of nsSNP haplotypes for
optimum K 6 1. Note the excess of admixed individuals for K+1.
Subgroups: Dark blue=1; Red=2; Green=3; Purple=4; Light
blue=POP5; Orange=6.
Found at: doi:10.1371/journal.pone.0008497.s003 (1.48 MB
PDF)
Figure S3 Comparison of Bayesian cluster and network analysis
for ten P. falciparum vaccine antigen genes. Subgroups: Dark
blue=1; Red=2; Green=3; Purple=4; Light blue=5;
Orange=6.
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Figure S4 Local population structure for P. falciparum vaccine
antigens based on Bayesian cluster analysis. Comparison of
Bayesian cluster and network analysis for ten P. falciparum vaccine
antigen genes. Networks (as shown in Figure 3) are shown with
individuals shaded by the structure-defined subgroups (as shown in
Figure 2). Subgroups: Dark blue=1; Red=2; Green=3;
Purple=4; Light blue=5; Orange=6; Admixed haplotypes (those
having ,75% membership to any one cluster) are shown in white,
vaccine haplotypes are shown in yellow.
Found at: doi:10.1371/journal.pone.0008497.s005 (0.90 MB TIF)
Table S1 Population dataset for twelve P. falciparum vaccine
antigen genes.
Found at: doi:10.1371/journal.pone.0008497.s006 (0.04 MB
XLS)
Table S2 Dataset 2: Sequences from laboratory and other
isolates for twelve P. falciparum vaccine antigen genes.
Found at: doi:10.1371/journal.pone.0008497.s007 (0.02 MB
XLS)
Table S3 Analysis of structure results for ten P. falciparum vaccine
antigens.
Found at: doi:10.1371/journal.pone.0008497.s008 (0.02 MB
XLS)
Table S4 Haplotype and cluster membership for laboratory
isolates.
Found at: doi:10.1371/journal.pone.0008497.s009 (0.03 MB
XLS)
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